S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers

Moushumi Suryavanshi, Julian Sanz-Ortega, Deepika Sirohi, Mukul K. Divatia, Chisato Ohe, Claudia Zampini, Daniel Luthringer, Steven C. Smith, Mahul Amin

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalAdvances in Anatomic Pathology
Volume24
Issue number3
DOIs
StatePublished - Jan 1 2017

Fingerprint

Uroplakin II
S100 Proteins
Differentiation Antigens
Differential Diagnosis
Carcinoma
Neoplasms

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

S100P as a Marker for Urothelial Histogenesis : A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers. / Suryavanshi, Moushumi; Sanz-Ortega, Julian; Sirohi, Deepika; Divatia, Mukul K.; Ohe, Chisato; Zampini, Claudia; Luthringer, Daniel; Smith, Steven C.; Amin, Mahul.

In: Advances in Anatomic Pathology, Vol. 24, No. 3, 01.01.2017, p. 151-160.

Research output: Contribution to journalReview article

Suryavanshi, Moushumi ; Sanz-Ortega, Julian ; Sirohi, Deepika ; Divatia, Mukul K. ; Ohe, Chisato ; Zampini, Claudia ; Luthringer, Daniel ; Smith, Steven C. ; Amin, Mahul. / S100P as a Marker for Urothelial Histogenesis : A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers. In: Advances in Anatomic Pathology. 2017 ; Vol. 24, No. 3. pp. 151-160.
@article{3dd5f7ec303c45c5b3195c5793f3e841,
title = "S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers",
abstract = "S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.",
author = "Moushumi Suryavanshi and Julian Sanz-Ortega and Deepika Sirohi and Divatia, {Mukul K.} and Chisato Ohe and Claudia Zampini and Daniel Luthringer and Smith, {Steven C.} and Mahul Amin",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/PAP.0000000000000150",
language = "English (US)",
volume = "24",
pages = "151--160",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - S100P as a Marker for Urothelial Histogenesis

T2 - A Critical Review and Comparison with Novel and Traditional Urothelial Immunohistochemical Markers

AU - Suryavanshi, Moushumi

AU - Sanz-Ortega, Julian

AU - Sirohi, Deepika

AU - Divatia, Mukul K.

AU - Ohe, Chisato

AU - Zampini, Claudia

AU - Luthringer, Daniel

AU - Smith, Steven C.

AU - Amin, Mahul

PY - 2017/1/1

Y1 - 2017/1/1

N2 - S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.

AB - S100P, or placental S100, is a member of a large family of S100 proteins and considered to be a promising immunohistochemical marker to support urothelial differentiation. This review synthesizes published data regarding the expression of S100P in urothelial carcinoma across histological grade and variant patterns, and in other malignancies, in an effort to summarize the state of understanding of this marker and evaluate its potential. We provide also a broad comparison of S100P with other contemporary and traditional urothelial markers and outline the potential utility of S100P in various diagnostically challenging scenarios. Taken in context, we recommend that to provide immunohistochemical support for consideration of urothelial differentiation, S100P may be included in a panel of markers (due to its high sensitivity), with better established (GATA3) and more specific (uroplakin 2) markers, for comparison with corresponding markers of other primary sites under consideration, depending on the clinical context. We emphasize that the overall most appropriate panel for any given case depends on the differential diagnosis engendered by the morphology encountered, and the constellation of clinical findings. As always with immunohistochemical panels, expected positive and negative markers for each diagnostic consideration should be included. Finally, since as of date there are no optimally sensitive or specific markers of urothelial differentiation, all final diagnoses relying on immunohistochemical support should be made in the appropriate clinical and histological context.

UR - http://www.scopus.com/inward/record.url?scp=85017375725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017375725&partnerID=8YFLogxK

U2 - 10.1097/PAP.0000000000000150

DO - 10.1097/PAP.0000000000000150

M3 - Review article

C2 - 28398953

AN - SCOPUS:85017375725

VL - 24

SP - 151

EP - 160

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 3

ER -